BACK TO EVENTSANALYZED · 30 Jul 2026, 1:04 pm IST
Impact 2/10 NEUTRAL intraday
Pulmonx reiterates $90M-$92M 2026 revenue outlook while targeting ~76% gross margin (NASDAQ:LUNG)
Pulmonx (LUNG) Q2 2026 earnings call: revenue $22.8M, guidance reaffirmed, margins up, China restart, AeriSeal TAM boost—read key takeaways.
Source articleAI_ANALYSIS · CLAUDE_SONNET
Impact Score
2/10
Sentiment
NEUTRAL
Confidence
55%
Impact Duration
intraday
Duration read: US-listed medical device stock with no direct India equity market impact.
AI SUMMARY
Pulmonx reaffirms 2026 revenue guidance of $90M-$92M with improving margins and China market restart; limited direct India market relevance.
AFFECTED_SECTORS
HealthcareMedical Devices
SIMILAR_HISTORICAL_EVENTS
- ›Medtronic quarterly earnings reaffirmation
- ›Boston Scientific guidance hold
- ›Invacare revenue outlook maintenance
SIMILAR_EVENTS_IN_JOURNAL
- MiMedx outlines 2027 revenue well in excess of $400M with over 20% adjusted EBITDA margin following planned Sanara deal (NASDAQ:MDXG)Impact 2/10 · Healthcare · Pharmaceuticals
- IPO rush next week: 9 companies to launch issues on Dalal Street, raising over Rs 11,000 croreImpact 6/10 · Healthcare · Renewable Energy · Electrical Equipment
- Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK)Impact 1/10 · Pharmaceuticals · Healthcare
- Baxter Stock: The Chart Points Higher, Valuation & Growth Are Less Appealing (NYSE:BAX)Impact 2/10 · Healthcare · Pharmaceuticals
- Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion BetImpact 2/10 · Pharmaceuticals · Healthcare